1. Carl W. Dieffenbach, Ph.D. Director Division of AIDS, NIAID July 2, 2013 HIV Vaccine and Future Strategies

2. This session will review past HIV vaccine efforts, as well as novel viral vectors and advances in the design of vaccines to induce neutralizing antibodies. A panel will discuss options to accelerate the development of a much needed HIV vaccine. ALVAC pox-based prime boost programme (RV144) Punnee Pitisuttithum, Thailand State of the art findings on HIV vaccines Glenda Gray, South Africa B cell response to vaccine candidates; antibody-based approaches Dennis Burton, United States Issues of engagement with populations at risk in HIV vaccine trials Mitchell Warren, United States Debate on future HIV vaccine strategies, including T response/other immune responses to vaccines Marcus Altfeld, United States Dennis Burton, United States Glenda Gray, South Africa Punnee Pitisuttithum, Thailand Mitchell Warren, United States

5. HIV Vaccine Efficacy Trials NOTE: Phambili (HVTN 503) began to explore a regime similar to STEP in South Africa (not included). No